Almirall has announced that Lebrikizumab achieves skin clearance in pivotal phase 3 atopic dermatitis trials

Almirall has announced that its phase 3 studies in atopic dermatitis show that lebrikizumab results in clearer skin for the majority of patients. The drug was used for patients with moderate-to-severe atopic dermatitis as part of Almirall